BioCardia Announces $4.4 Million Financing
Rhea-AI Summary
BioCardia (Nasdaq: BCDA) completed a $4.4 million equity financing, selling 3,509,604 shares at an average price of $1.279 on June 5, 2026. Net proceeds are anticipated to extend the company’s cash runway into the first quarter of 2027, beyond the expected Japan PMDA submission. If currently outstanding warrants from prior financings are exercised for cash, BioCardia anticipates cash runway extending beyond PMDA approval and into initial commercial sales. No new warrants were issued in this capital raise.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Positive
- $4.4 million equity financing completed for additional capital
- 3,509,604 shares sold at $1.279 average price on June 5, 2026
- Net proceeds expected to fund operations into Q1 2027
- Runway expected to extend beyond planned Japan PMDA submission
- Full cash exercise of prior warrants could fund into first commercial sales
- No new warrants issued, limiting additional warrant overhang
Negative
- Issuance of 3,509,604 new shares creates immediate shareholder dilution
- Further runway extension depends on cash exercise of existing warrants
News Market Reaction – BCDA
On the day this news was published, BCDA declined 12.63%, reflecting a significant negative market reaction. Argus tracked a trough of -19.5% from its starting point during tracking. Our momentum scanner triggered 16 alerts that day, indicating notable trading interest and price volatility. This price movement removed approximately $2M from the company's valuation, bringing the market cap to $11.72M at that time.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| 2026-06-05 | Regulatory FDA update | Positive | +12.1% | FDA minutes indicated CardiAMP HF II may support PMA for HFrEF. |
| 2026-05-28 | Japan PMDA guidance | Positive | +1.8% | PMDA record supported Q4 2026 regulatory submission for CardiAMP in Japan. |
| 2026-05-21 | Clinical trial data | Positive | -0.9% | CardiAMP CMI trial showed durable exercise and angina improvements. |
| 2026-05-19 | Investor conference | Neutral | +5.6% | Company participated in an A.G.P. Healthcare fireside chat. |
| 2026-05-15 | Earnings and update | Negative | -7.3% | Q1 2026 results showed narrower loss but a weaker balance sheet. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent news reactions mostly aligned with underlying news tone, with regulatory and clinical positives often followed by gains and only one notable divergence.
Over the last month, BioCardia announced multiple regulatory and clinical milestones. On May 15, 2026, Q1 results showed a narrower net loss but pressure on the balance sheet. Subsequent updates on CardiAMP clinical data and conference participation built visibility. On May 28, Japan’s PMDA supported a Q4 2026 submission, followed by June 5 FDA minutes indicating the CardiAMP HF II trial may support PMA. These events collectively frame today’s financing against a backdrop of advancing late-stage programs and prior capital constraints.
Regulatory & Risk Context
Key Terms
warrants financial
pmda regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
Net proceeds anticipated to extend cash runway into first quarter of 2027 beyond expected Japan PMDA submission; if currently outstanding warrants issued in previous financings are exercised in full for cash, it is anticipated that the cash runway would extend well beyond PMDA approval and into first commercial sales.
SUNNYVALE, Calif., June 08, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases, sold 3,509,604 shares at an average price of
About BioCardia®
BioCardia, Inc., headquartered in Sunnyvale, California, is a global leader in cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary disease. CardiAMP® autologous and CardiALLO™ allogeneic cell therapies are the Company’s biotherapeutic platforms with three cardiac clinical stage product candidates in development. These therapies are enabled by its Helix™ biotherapeutic delivery and Morph® vascular navigation product platforms, and soon the Heart3D™ fusion imaging platform. BioCardia selectively partners on biotherapeutic delivery with peers developing important biologic therapies. For more information visit www.biocardia.com.
Upcoming Catalysts in 2026:
- CardiAMP HF Manuscript Published
- CardiAMP HF Japan PMDA Submission Q4 2026
Forward Looking Statements:
This press release contains forward-looking statements that are subject to many risks and uncertainties. Forward-looking statements include, among other things, statements relating to submission for and subsequent market clearance of the CardiAMP Cell Therapy. These forward-looking statements are made as of the date of this press release.
We may use terms such as “believes,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” “approximately” or other words that convey the uncertainty of future events or outcomes to identify these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained herein, we caution you that forward-looking statements are not guarantees of future performance and that our actual results may differ materially from the forward-looking statements contained in this press release. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s liquidity position and its ability to raise additional funds, as well as the Company’s ability to successfully progress its clinical trials. As a result of these factors, we cannot assure you that the forward-looking statements in this press release will prove to be accurate. Additional factors that could materially affect actual results can be found in BioCardia’s Form 10-K filed with the Securities and Exchange Commission on March 24, 2026, under the caption titled “Risk Factors” and in its subsequently filed Quarterly Reports on Form 10-Q. BioCardia expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law.
Media Contact:
Miranda Peto, Investor Relations
Email: mpeto@BioCardia.com
Phone: 650-226-0120
Investor Contact:
David McClung, Chief Financial Officer
Email: investors@BioCardia.com
Phone: 650-226-0120
